Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
March 06, 2019 at 08:11 AM EST
The company said in an open letter to shareholders, its board of directors are "confident" the drugmakers acquisition of Celgene is the best path forward.